CAS No.: 160970-54-7
Category: Alpha-1 Adrenergic Receptor Blocker
Molecular Formula: C₂₅H₃₂F₃N₃O₄
Molecular Weight: 495.53 g/mol
Synonyms: KMD-3213, KAD-3213
Silodosin is a selective alpha-1 adrenergic receptor antagonist primarily targeting the α1A receptor subtype. It is used to improve urinary symptoms associated with benign prostatic hyperplasia (BPH) by relaxing smooth muscle in the prostate and lower urinary tract.
Silodosin has a high affinity for the α1A subtype of alpha-1 adrenergic receptors, which are predominantly associated with the prostate, bladder neck, bladder base, prostatic capsule and prostatic urethra.
Silodosin is primarily used in urological and pharmaceutical applications, particularly for the management and research of lower urinary tract symptoms associated with BPH.
Silodosin’s selective activity at α1A receptors helps relax smooth muscle in the prostate and bladder outlet, improving urinary flow and reducing BPH symptoms.
Silodosin is a pharmacologically active alpha-adrenergic antagonist and should be handled according to the applicable SDS and pharmaceutical safety procedures.
Silodosin can cause postural hypotension and dizziness, particularly around treatment initiation. Patients should be appropriately cautioned about activities such as driving or operating machinery until they know how the medicine affects them.
Silodosin is also contraindicated in patients with severe renal or hepatic impairment according to product labeling, so pharmaceutical use should follow approved prescribing information.
Silodosin works primarily by selectively blocking post-synaptic α1A adrenergic receptors.
Silodosin binds with high affinity to the α1A subtype of alpha-1 adrenergic receptors. These receptors are found in the prostate, bladder neck, bladder base, prostatic capsule and prostatic urethra.
Blocking α1A receptors reduces adrenergic smooth-muscle tone in the prostate and bladder outlet.
The resulting relaxation decreases resistance to urine flow and helps reduce lower urinary tract symptoms associated with BPH.
Silodosin → α1A receptor blockade → prostate/bladder-neck smooth muscle relaxation → reduced urinary resistance → improved urine flow
Silodosin is a selective α1A adrenergic receptor antagonist primarily used to treat urinary symptoms associated with benign prostatic hyperplasia.
The CAS number is 160970-54-7.
The molecular formula is C₂₅H₃₂F₃N₃O₄.
The molecular weight is approximately 495.53 g/mol.
Silodosin is primarily used for the treatment of signs and symptoms of benign prostatic hyperplasia (BPH).
Silodosin selectively blocks post-synaptic α1 adrenergic receptors, particularly α1A receptors, causing smooth muscle relaxation in the prostate and bladder outlet.
Silodosin has high affinity for the α1A adrenergic receptor subtype.
Silodosin is described as a white to pale yellowish-white powder.
Protect Silodosin from light and moisture and store under controlled room-temperature conditions, subject to the specific product’s validated storage requirements.
Silodosin has been associated with the development codes KMD-3213 and KAD-3213.
R)-2-Hydroxy-N-(4-nitrophenethyl)-2-phenylacetamide is a chiral pharmaceutical intermediate associated with the synthesis of Mirabegron. It contains a stereochemically defined hydroxyphenylacetamide structure and a nitrophenethyl
Methyl 2-[4-(4-chlorobutanoyl)phenyl]-2-methylpropanoate is a chlorinated aromatic ketone ester used as a pharmaceutical intermediate in the synthesis of fexofenadine hydrochloride. It provides a
2-Chloromethyl-3,4-dimethoxypyridine hydrochloride is a pyridine-based pharmaceutical intermediate used in the synthesis of pantoprazole sodium. It serves as a chemical building block in
